or FDA-indicated XOI dose, and who have continued frequent gout flares (>2 flares/year) OR who have nonresolving subcutaneous tophi. Several lesinurad studies demonstrated the benefit of adding a uricosuric medication to XOI treatment 5 2 http://onlinelibrary.wiley.com/ doi/10.1002/acr.24180/abstract Switching to pegloticase over continuing current ULT is strongly recommended for patients with gout for whom XOI treatment, uricosurics, and other interventions have failed to achieve the SU